Lymphoma & Plasma Cell Disorders
News
Similar results for once- or twice-weekly carfilzomib in MM
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
News
Haplo-HCT shows viability in DLBCL
Survival rates were similar for matched and unmatched donors.
News
Researchers characterize new subtype of high-grade DLBCL
Patients with this subtype had distinct molecular features and poor prognosis.
News
CAR T-cell therapies difficult to compare
Article
Advances in CAR T-Cell Therapies
Clinical Topics & News
The Use of Immuno-Oncology Treatments in the VA
Article
10 Important VA Studies You Might Have Missed at ASH
Lost amid the headlining news at the Association American Society of Hematology meeting last week were significant research findings from VA...
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
Conference Coverage
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
Conference Coverage
TOURMALINE-MM3: Ixazomib improves PFS after myeloma transplant
SAN DIEGO – A leading investigator put the results in perspective with the currently approved lenalidomide, and the audience questions as to...
